Dupilumab Improves Clinical and Histologic Aspects of Disease in Adult and Adolescent Patients With Eosinophilic Esophagitis at Week 24: Results from Part B of the 3-Part LIBERTY EoE TREET Study
Marc E. Rothenberg(Cincinnati Children's Hospital Medical Center), Arsalan Shabbir(Regeneron (United States)), Ikuo Hirano(Northwestern University), Elizabeth Laws(Sanofi (United States)), Jennifer D. Hamilton(Regeneron (United States)), Albert J. Bredenoord(Amsterdam Neuroscience), Bethany Beazley(Regeneron (United States)), Jonathan M. Spergel(University of Pennsylvania), Alfredo J. Lucendo(Hospital General de Tomelloso), Bolanle Akinlade(Regeneron (United States)), Leda Mannent(Sanofi (France)), Angeliki Giannelou(Northwestern University), Eilish McCann(Regeneron (United States)), Xian Sun(Regeneron (United States)), Nikhil Amin(Northwestern University), Mirna Chehade(Icahn School of Medicine at Mount Sinai), Margaret Collins(Cincinnati Children's Hospital Medical Center), Urvi Mujumdar(Memorial Sloan Kettering Cancer Center), Kiran Patel(Goethe University Frankfurt), Evan S. Dellon(University of North Carolina at Chapel Hill)
Cited by 12
Related Papers
Eosinophilic esophagitis: Updated consensus recommendations for children and adults
|Journal of Allergy and Clinical Immunology|2011|2.1k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Burden of Gastrointestinal Disease in the United States: 2012 Update
|Gastroenterology|2012|2k
Burden and Cost of Gastrointestinal, Liver, and Pancreatic Diseases in the United States: Update 2018
|Gastroenterology|2018|1.7k